Although GM-CSF treatment evidently improves learning/memory in mouse models of AD by removing amyloid plaques in the brain, it is noteworthy that WT mice and mouse models of DS, including Dp16 mice, do not develop AD amyloid pathology at any age. The gene discussed is CSF2; the disease is Alzheimer disease.